(2) commercial operations using the fuels, tar-
gets, and processes described in paragraph (1). 
(c) URANIUM LEASE AND TAKE BACK.—The Sec-
retary of Energy shall establish a program to make low 
enriched uranium available, through lease contracts, for 
irradiation for the production of molybdenum-99 for med-
ical uses. The lease contracts shall provide for the Sec-
retary to retain responsibility for the final disposition of 
radioactive waste created by the irradiation, processing, 
or purification of leased uranium. 
SEC. 4. EXPORTS. 
Section 134 of the Atomic Energy Act of 1954 (42 
U.S.C. 2160d(b)) is amended by striking subsections b. 
and c. and inserting in lieu thereof the following: 
‘‘b. Effective 7 years after the date of enactment of 
the American Medical Isotopes Production Act of 2009, 
the Commission may not issue a license for the export of 
highly enriched uranium from the United States. 
‘‘c. The period referred to in subsection (b) may be 
extended for no more than three years if, no earlier than 
6 years after the date of enactment of the Act, the Sec-
retary of Energy certifies to the appropriate Congressional 
committees that— 
‘‘(1) there is insufficient global supply of molyb-
denum-99 produced without the use of highly en-
VerDate Nov 24 2008 
03:39 Jul 22, 2009
Jkt 079200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H3276.IH
H3276
smartinez on DSKB9S0YB1PROD with BILLS
riched uranium available to satisfy the domestic 
United States market, and 
‘‘(2) the export of United States-origin highly 
enriched uranium for the purposes of medical iso-
tope production is the most effective temporary 
means to increase the supply of molybdenum-99 to 
the domestic United States market.’’. 
SEC. 5. REPORT ON DISPOSITION OF EXPORTS. 
Not later than 1 year after the date of the enactment 
of this Act, the Chairman of the Nuclear Regulatory Com-
mission, after consulting with other relevant agencies, 
shall submit to the Congress a report detailing the current 
disposition of previous United States exports of highly en-
riched uranium, including— 
(1) their location; 
(2) whether they are irradiated; 
(3) whether they have been used for the pur-
pose stated in their export license; 
(4) whether they have been used for an alter-
native purpose and, if so, whether such alternative 
purpose has been explicitly approved by the Commis-
sion; 
(5) the year of export, and reimportation, if ap-
plicable; 
VerDate Nov 24 2008 
03:39 Jul 22, 2009
Jkt 079200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H3276.IH
H3276
smartinez on DSKB9S0YB1PROD with BILLS
(6) their current physical and chemical forms; 
and 
(7) whether they are being stored in a manner 
which adequately protects against theft and unau-
thorized access. 
SEC. 6. DOMESTIC MEDICAL ISOTOPE PRODUCTION. 
(a) IN GENERAL.—Chapter 10 of the Atomic Energy 
Act of 1954 (42 U.S.C. 2131 et seq.) is amended by add-
ing at the end the following new section: 
‘‘SEC. 112. DOMESTIC MEDICAL ISOTOPE PRODUC-
TION. a. The Commission may issue a license, or grant 
an amendment to an existing license, for the use in the 
United States of highly enriched uranium as a target for 
medical isotope production in a nuclear reactor, only if, 
in addition to any other requirement of this Act— 
‘‘(1) the Commission determines that— 
‘‘(A) there is no alternative medical isotope 
production target, enriched in the isotope U- 
235 to less than 20 percent, that can be used 
in that reactor; and 
‘‘(B) the proposed recipient of the medical 
isotope production target has provided assur-
ances that, whenever an alternative medical iso-
tope production target can be used in that reac-
VerDate Nov 24 2008 
03:39 Jul 22, 2009
Jkt 079200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H3276.IH
H3276
smartinez on DSKB9S0YB1PROD with BILLS
tor, it will use that alternative in lieu of highly 
enriched uranium; and 
‘‘(2) the Secretary of Energy has certified that 
the United States Government is actively supporting 
the development of an alternative medical isotope 
production target that can be used in that reactor. 
‘‘b. As used in this section— 
‘‘(1) the term ‘alternative medical isotope pro-
duction target’ means a nuclear reactor target which 
is enriched to less than 20 percent of the isotope U- 
235; and 
‘‘(2) a target ‘can be used’ in a nuclear re-
search or test reactor if— 
‘‘(A) the target has been qualified by the 
Reduced Enrichment Research and Test Reac-
tor Program of the Department of Energy; and 
‘‘(B) use of the target will permit the large 
majority of ongoing and planned experiments 
and isotope production to be conducted in the 
reactor without a large percentage increase in 
the total cost of operating the reactor.’’. 
(b) TABLE OF CONTENTS.—The table of contents for 
the Atomic Energy Act of 1954 is amended by inserting 
the following new item after the item relating to section 
111: 
‘‘Sec. 112. Domestic medical isotope production.’’. 
VerDate Nov 24 2008 
03:39 Jul 22, 2009
Jkt 079200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6211
E:\BILLS\H3276.IH
H3276
smartinez on DSKB9S0YB1PROD with BILLS
SEC. 7. ANNUAL DEPARTMENT OF ENERGY REPORTS. 
The Secretary of Energy shall report to Congress no 
later than one year after the date of enactment of this 
Act, and annually thereafter for 5 years, on Department 
of Energy actions to support the production in the United 
States, without the use of highly enriched uranium, of mo-
lybdenum-99 for medical uses. These reports shall include 
the following: 
(1) For medical isotope development projects— 
(A) the names of any recipients of Depart-
ment of Energy support under section 3 of this 
Act; 
(B) the amount of Department of Energy 
funding committed to each project; 
(C) the milestones expected to be reached 
for each project during the year for which sup-
port is provided; 
(D) how each project is expected to sup-
port the increased production of molybdenum- 
99 for medical uses; 
(E) the findings of the evaluation of 
projects under section 3(a)(2) of this Act; and 
(F) the ultimate use of any Department of 
Energy funds used to support projects under 
section 3 of this Act. 
VerDate Nov 24 2008 
03:39 Jul 22, 2009
Jkt 079200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H3276.IH
H3276
smartinez on DSKB9S0YB1PROD with BILLS